$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
曲美替尼+达拉非尼作为西班牙转移性黑色素瘤患者慈善用药
2025-10-19 11:44:20
Check Details
曲美替尼在日本吉西他滨难治性晚期胆道癌患者中的疗效和安全性
2025-10-19 11:44:20
Check Details
曲美替尼+达拉非尼后伊匹单抗治疗黑色素瘤完全反应但出现胃肠道毒性
2025-10-19 11:44:20
Check Details
曲美替尼+达拉非尼治疗BRAF V600E突变低级别浆液性卵巢癌患者
2025-10-19 11:44:20
Check Details
曲美替尼+达拉非尼用于BRAFV600E突变黑色素瘤:治疗停止后长期完全反应
2025-10-19 11:44:20
Check Details
曲美替尼+达拉非尼治疗BRAF V600E突变MSI-H高转移性子宫内膜癌患者
2025-10-19 11:44:20
Check Details
曲美替尼+二甲双胍治疗化疗难治性卵巢透明细胞癌患者:高通量测序的应用
2025-10-19 11:44:20
Check Details
曲美替尼+达拉非尼治疗BRAF V600E突变胆管癌:个性化精准医疗
2025-10-19 11:44:20
Check Details
曲美替尼治疗NRAS突变复发性低疾病浆液性卵巢癌:病例报告
2025-10-19 11:44:20
Check Details
曲美替尼+达拉非尼治疗伴脑干受累的脂质肉芽肿病
2025-10-19 11:44:20
Check Details
达拉非尼说明书服法
2025-10-19 11:44:20
Check Details
达拉非尼说明书储存
2025-10-19 11:44:20
Check Details
1
2
...
6333
6334
6335
6336
6337
6338
6339
...
10232
10233
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
2
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance
3
Lorlatinib Contraindications and Safety Warnings: Six Key Risks to Monitor
4
AZA+VEN+IVO Triplet Therapy for Newly Diagnosed IDH1 AML: High Response Rates and Durable Efficacy
5
Dacomitinib for EGFR-Mutant NSCLC: Dosing, Switching, and Safety Profile
6
Abemaciclib for HR+ HER2- Breast Cancer: Mechanism, Combination Therapy, and Switching Considerations
7
Fezolinetant (Veozah) Dosing and Liver Monitoring Guide
8
Lusutrombopag Safety and Dosing: Thrombosis Risk and Indications
9
Mirogabalin for Neuropathic Pain: Onset Time and Dosing Strategy
10
Cemiplimab Mechanism of Action: How PD-1 Inhibition Restores Antitumor Immunity
11
Tivozanib Dosing Guide for Renal Cell Carcinoma: 21-Day On/7-Day Off Cycle and Adjustments
12
Anagrelide and Myelofibrosis Risk: Controversy and Monitoring in ET Treatment